Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 1998

View Archived Issues

Results published from phase II trial of Immune Response's rheumatoid arthritis treatment

First patient treated in phase II HIV gene therapy study

Abbott purchases additional La Jolla stock

AngioMARK significantly improves imaging of vascular structures in phase II trial

Jenner Biotherapies receives patent on improved vaccine formulation

SB launches smoking cessation line in European markets

Naphthylpiperazine antipsychotics synthesized at Faes

Pfizer claims new series for BPH with selective prostatic alpha1-adrenoceptor-antagonist effects

Orion launches entacapone in first markets and updates safety information

Lilly describes use of dihydrobenzo[b]indenothiophenes for estrogen-related pathologies

Piperidine derivatives from Sanofi useful for neurokinin-dependent pathologies

New antiparasitic agents in development at Bayer

FDA completes review of BioTime's NDA for Hextend

Dual ACE/NEP inhibitor compared to ACE inhibitor for efficacy in hypertension

Tamsulosin improves signs and symptoms of BPH in phase III study

ABS receives funding from NIH to support development of Alzheimer's drug

AN-9 compared to butyric acid and paclitaxel against primary human tumor colony-forming units

Preclinical studies of XV-454 support further testing of novel fibrinogen antagonist

Combretastatin preclinical studies demonstrate antitumor efficacy when combined with radiation

Dual 5-LO/COX inhibitor from Eisai displays potent antiinflammatory efficacy in vivo

FDA informs Ligand that Panretin Gel is approvable

SB submits novel type II diabetes Rx for FDA approval

Phase II prostate cancer trial of Atragen now in progress

One Alkermes-R.W. Johnson collaboration makes progress, while another is terminated

AMBI seeks partners to develop oral nisin for colon infections

Another market introduction for Lilly's SERM for postmenopausal women

Asthma program accelerated by Genome Therapeutics and Schering-Plough

Chiron completes sale of diagnostics business to Bayer

Vical reports delivery of cytokine and antitumor activity using naked DNA gene transfer

Late-breaking news: Hoechst and Rhone-Poulenc announce creation of Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...